안티센스 및 RNAi 치료제 시장 : 기술, 투여 경로, 용도, 세계 예측(2024-2032년)

Global Antisense and RNAi Therapeutics Market will grow at an 18.2% CAGR during 2024 and 2032, propelled by growing research and development coupled with the expansion of clinical trials. Continuous R&D efforts lead to the discovery of innovative therapies and improvements in delivery mechanisms, enhancing the efficacy of antisense and RNAi treatments. Moreover, the expansion of clinical trials validates these advancements and supports their progression through regulatory pathways. This synergy of ongoing research and robust trial activities fosters market growth, increasing the availability and adoption of these advanced therapeutic solutions.

For instance, in August 2023, Sirnaomics Ltd. successfully completed Phase I of its STP707 RNAi therapeutic study, showing positive results in treating multiple solid tumors in late-stage cancer patients unresponsive to previous treatments. This development highlights the potential of RNAi therapies to address complex oncology cases where other treatments have failed, enhancing the appeal of RNAi-based solutions. It may drive increased investment and research in RNAi therapeutics, expand market opportunities, and validate the effectiveness of RNAi technology in cancer treatment.

The antisense and RNAi therapeutics industry is divided based on technology, route of administration, application, and region.

The subcutaneous injections segment will experience a marked upturn through 2032, driven by its practicality and patient-friendly nature. Subcutaneous injections allow for the administration of therapeutics with relatively simple techniques and minimal discomfort, making them ideal for long-term treatments. This route of delivery is also well-suited for therapies requiring frequent dosing or self-administration, enhancing patient adherence. As antisense and RNAi therapeutics advance, the convenience and efficiency of subcutaneous injections position them as the preferred method for widespread clinical use.

The cancer segment will witness a considerable surge between 2024 and 2032, attributed to the increasing demand for targeted treatments in oncology. Antisense and RNAi technologies offer precise mechanisms for silencing genes associated with cancer progression, providing innovative treatment approaches. As the understanding of cancer genomics advances, these therapies are becoming crucial for developing personalized medicine strategies. The significant potential for improving patient outcomes and overcoming drug resistance in cancer treatment drives the dominance of this segment in the market.

Asia Pacific antisense and RNAi therapeutics market share will register a noteworthy CAGR from 2024 to 2032, owing to the country's rapidly growing healthcare sector and increasing investment in biotechnology. The region's expanding patient population, rising prevalence of chronic diseases, and supportive government policies drive the demand for advanced therapeutic solutions. Additionally, substantial research and development activities, coupled with improvements in healthcare infrastructure, further boost market growth. Asia Pacific's strategic advancements and investments make it a vital contributor to the expansion of the antisense and RNAi therapeutics industry.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of neurodegenerative and genetic disorders
    • 3.2.1.2 Growing investments in research related to gene expression and delivery technologies
    • 3.2.1.3 Growth in regulatory approvals for RNAi and antisense therapeutics
    • 3.2.1.4 Rising awareness towards RNA-based therapeutics
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Requirement for significant investments in clinical studies
    • 3.2.2.2 High cost of RNA-based therapies
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 RNA interference
• 5.3 Antisense RNA

Chapter 6 Market Estimates and Forecast, By Route of administration, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Intravenous injections
• 6.3 Intrathecal injections
• 6.4 Subcutaneous injections
• 6.5 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Cardiometabolic & renal disorders
• 7.3 Cancer
• 7.4 Neurodegenerative disorders
• 7.5 Genetic disorders
• 7.6 Infectious diseases
• 7.7 Ophthalmic diseases
• 7.8 Skin diseases
• 7.9 Other applications

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Alnylam Pharmaceuticals, Inc.
• 9.2 Arbutus Biopharma
• 9.3 Arrowhead Pharmaceuticals, Inc.
• 9.4 Benitec Biopharma Inc.
• 9.5 BioNTech SE.
• 9.6 CRISPR Therapeutics
• 9.7 GlaxoSmithKline plc
• 9.8 Ionis Pharmaceuticals, Inc.
• 9.9 Novartis AG
• 9.10 OliX Pharmaceuticals, Inc.
• 9.11 Orna Therapeutics, Inc.
• 9.12 Percheron Therapeutics Ltd.
• 9.13 Sanofi
• 9.14 Sarepta Therapeutics, Inc.
• 9.15 Silence Therapeutics